HIGH POINT, N.C., Sept. 03, 2025 (GLOBE NEWSWIRE) — vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that management will participate in the following September investor conferences: H.C. Wainwright 27th Annual Global Investment ConferenceDate:Tuesday, September 9, 2025Format:1×1 Investor Meetings Only Morgan Stanley 23rd Annual Global Healthcare Conference Date:Wednesday, September 10, 2025Format:Fireside Chat Time: 2:35 PM – 3:10 PM EST and 1×1 Investor Meetings About vTv TherapeuticsvTv Therapeutics is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. vTv’s clinical pipeline is led by cadisegliatin, currently in a Phase 3 trial, a potential first-in-class oral glucokinase activator being investigated for the treatment of type 1 diabetes. vTv and its development partners are investigating multiple molecules across different indications for chronic diseases. Learn more at vtvtherapeutics.com or follow the company on LinkedIn or X. Investor ContactJohn FrauncesLifeSci Advisors, LLCjfraunces@lifesciadvisors.com Media ContactCaren BegunTellMed Strategies201-396-8551caren.begun@tmstrat.com